SCHEMBL10003648

SCHEMBL10003648

CCc1nc2c(nc1-c1ccc(Cl)cc1)c(OC(C)C)c(C(=O)O)n2C

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GABRA2 P47869 3/20 0.39
▸ GABRB2 P47870 3/20 0.39
▸ SELPLG Q14242 1/20 0.38
▸ GRIA2 P42262 1/20 0.37
▸ GRIA4 P48058 1/20 0.37
▸ DHODH Q02127 2/20 0.33
▸ CYP1A2 P05177 1/20 0.33
▸ CYP3A4 P08684 1/20 0.33
▸ CYP2C8 P10632 1/20 0.33
▸ CYP2D6 P10635 1/20 0.33
▸ CYP2A6 P11509 1/20 0.33
▸ CYP2C9 P11712 1/20 0.33
▸ CYP2C19 P33261 1/20 0.33
▸ MDM2 Q00987 2/20 0.33
▸ KCNK3 O14649 1/20 0.33
▸ KCNK9 Q9NPC2 1/20 0.33
▸ KDM4E B2RXH2 1/20 0.33
▸ ALDH1A1 P00352 1/20 0.33
▸ HSD17B10 Q99714 1/20 0.33
▸ CNR1 P21554 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10004654 0.90 GRIA2 (0.37) GABRA2GABRB2GRIA2GRIA4DHODH
SCHEMBL10003794 0.89 GABRA2 (0.45) GABRA2GABRB2DHODHCYP1A2CYP2C9
SCHEMBL10003388 0.79 GABRA2 (0.45) GABRA2GABRB2CYP1A2CYP3A4CYP2D6
SCHEMBL10003185 0.79 KDM4E (0.41) KDM4EHSD17B10CNR1
SCHEMBL10003130 0.76 BCL2 (0.38) GABRA2GABRB2GRIA2GRIA4DHODH
SCHEMBL10004170 0.74 USP2 (0.37) GABRA2GABRB2KDM4EALDH1A1HSD17B10
SCHEMBL10003341 0.74 GRIA2 (0.38) GABRA2GABRB2GRIA2GRIA4DHODH
SCHEMBL10003232 0.73 CACNA1G (0.35) GABRA2GABRB2GRIA2GRIA4CYP1A2
SCHEMBL10003385 0.72 TMIGD3 (0.38) KDM4EALDH1A1
SCHEMBL10003857 0.72 MCL1 (0.36) GABRA2GABRB2DHODHCYP1A2CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2471789-B9 FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL (JP) 2015-03-25 — — EP disclosed
EP-2471789-B1 FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL (JP) 2014-09-17 — — EP disclosed
US-8486965-B2 Pyrrolo[2,3-b]pyridine derivative and use thereof for treatment of cancer TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-07-16 — — US disclosed
US-20120220569-A1 FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-08-30 — — US disclosed
EP-2471789-A1 FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2012-07-04 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120220569-A1 FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF SMO, GLI1, SHH GABRA2 2197/4885GABRB2 1779/4885SELPLG 1908/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback